Data supports further development of CYT-338 in relapsed/ref

Data supports further development of CYT-338 in relapsed/refractory multiple myeloma

Related Keywords

China , New York , United States , Puerto Rico , Jerusalem , Israel General , Israel , Austria , Vienna , Wien , , Instagram , I Cytovia Therapeutics Inc , York Stem Cell Foundation , Linkedin , Twitter , European Hematology Association , Youtube , Hebrew University Of Jerusalem , Facebook , University Of California San Francisco , United Statesi June , Cytovia Therapeutics , Abstract Code , Hebrew University , New York Stem Cell Foundation , California San Francisco , Cytolynx Therapeutics , Greater China , Biologics , Antibodies , Therapeutic Antibodies , Recombinant , Antibody Drug Conjugates , Dc , Immunoconjugates , Biosimilar Antibodies , Biosuperior Antibodies , Antibody Fragments , Scfv , Lab , Nanobodies , Domain Antibodies , Manufacturing ,